Pancreatic Cancer Research

ResearcherMedical University of South CarolinaActive in the last 2 years

Christabelle Rajesh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5211-4454; OpenAlex author ID A5065508915. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 3 papers

Papers 8

  1. MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2026.218927↗
  2. KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. Co-author DOI 10.1158/0008-5472.can-25-2630↗
  3. Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-1181↗
  4. Unraveling the glyco-immunity nexus in pancreatic cancer. Co-author DOI 10.1186/s12943-025-02417-4↗
  5. Humanized Anti-MUC16 Antibody-Conjugated Contrast Agents for Magnetic Resonance Imaging of Pancreatic Cancer. First author DOI 10.3390/cancers17060957↗
  6. Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6. Co-author DOI 10.1158/1535-7163.mct-23-0868↗
  7. Truncated O-Glycan-Bearing MUC16 Enhances Pancreatic Cancer Cells Aggressiveness via α4β1 Integrin Complexes and FAK Signaling. Co-author DOI 10.3390/ijms23105459↗
  8. Structure activity relationship (SAR) study identifies a quinoxaline urea analog that modulates IKKβ phosphorylation for pancreatic cancer therapy. Co-author DOI 10.1016/j.ejmech.2021.113579↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Prakash Radhakrishnan · 6 shared papers, 2021–2026 · strength 1.37
  2. Michael Anthony Hollingsworth · 5 shared papers, 2022–2026 · strength 1.04
  3. Satish Sagar · 5 shared papers, 2021–2026 · strength 0.95
  4. Richard D. Cummings · 1 shared paper, 2025 · strength 0.42
  5. Thomas C. Caffrey · 2 shared papers, 2024–2025 · strength 0.42
  6. Thomas B. McFall · 2 shared papers, 2026 · strength 0.41
  7. G. Aaron Hobbs · 2 shared papers, 2026 · strength 0.41
  8. Clara S. Mundry · 1 shared paper, 2026 · strength 0.25
  9. Ying Huang · 1 shared paper, 2026 · strength 0.25
  10. Jayasindu Mathiyazhagan · 1 shared paper, 2025 · strength 0.25
  11. Aaron M. Mohs · 1 shared paper, 2025 · strength 0.25
  12. Lu Han · 1 shared paper, 2026 · strength 0.21
  13. David F. Kashatus · 1 shared paper, 2026 · strength 0.21
  14. Rachel A. Burge · 1 shared paper, 2026 · strength 0.21
  15. Victoria K. Spadafora · 1 shared paper, 2026 · strength 0.21
  16. Denis C. Guttridge D · 1 shared paper, 2026 · strength 0.21
  17. Christopher M Counter · 1 shared paper, 2026 · strength 0.21
  18. Channing J. Der · 1 shared paper, 2026 · strength 0.21
  19. Todd W. Bauer · 1 shared paper, 2026 · strength 0.21
  20. Michael C. Ostrowski · 1 shared paper, 2026 · strength 0.21
  21. Nikki K. Lytle · 1 shared paper, 2026 · strength 0.20
  22. Brian F Volkman · 1 shared paper, 2026 · strength 0.20
  23. Yongwoo David Seo · 1 shared paper, 2026 · strength 0.20
  24. Daniel Dorbin · 1 shared paper, 2026 · strength 0.20
  25. Mohammed Aldakkak · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.